Longfei Fang

Longfei Fang joined Goodwin in 2022 as a department attorney in the firm’s Technology and Life Sciences groups.

Longfei represents biotechnology and pharmaceutical companies in connection with mergers and acquisitions, technology-based transactions, licensing and strategic partnerships as well as financing transactions.

Longfei’s representative transactions include:

• Biotheus Inc. in a strategic research collaboration, option and worldwide license agreement with BioNTech SE.
• C4 Therapeutics in its Licensing Agreement with Betta Pharmaceuticals
• DualityBio Biologics in its license and collaboration agreements with BioNTech SE.
• DualityBio Biologics in its exclusive option, license and collaboration agreement with BeiGene
• Inventisbio in its license and collaboration agreement with Chia-Tai Tianqing Pharmaceutical Group
• Luye Pharma Group in its license agreement with BeiGene, Ltd.
• Kelun-Biotech in its license and collaboration agreement with Merck & Co, Inc.
• Biosion USA, Inc. in its research and collaboration agreement with ImmunoGen, Inc.

Prior to joining Goodwin, Longfei was at another leading international law firm, where he focused on representing clients in cross-border patent litigation and intellectual property, M&A, and commercial transactions.

While attending law school, Longfei served as an Editor for the Columbia Science and Technology Law Review.